ClinicalTrials.gg
TerminatedNCT03960606Updated Aug 27, 2021

Study in Adult Asthmatic Patients With Allergic Bronchopulmonary Aspergillosis

A Phase 2 interventional study of PUR1900 and Placebo in Allergic Bronchopulmonary Aspergillosis, sponsored by Pulmatrix Inc.. Terminated at 20 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-08-27.

Sponsored by Pulmatrix Inc. · Phase 2, Interventional, and Treatment

Why this study was terminated
COVID-19 Pandemic

From the registry’s dates

  • Primary completion was Jul 2020, 6 years 4 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Jul 2021.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
7
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Aspergillosis, Allergic Bronchopulmonary with a site in United States — none open to participants now, none under way, none of them phase 3. Aspergillosis, Allergic Bronchopulmonary · United States.

Started
2019
with 1 other
Phase 2
3 of 10
none open now
Registered
6th of 10
by date
Lead sponsor
2 of 10
Pulmatrix Inc.

Among the 10 studies in Aspergillosis, Allergic Bronchopulmonary with a site in United States, this one is one of 2 that started in 2019, is one of 3 in phase 2, and was the 6th registered.

Aspergillosis, Allergic Bronchopulmonary

42 studies on the registry are indexed under Aspergillosis, Allergic Bronchopulmonary; 13 are open to participants now.

Browse Aspergillosis, Allergic Bronchopulmonary studies →

Open to participants now

None of the 10 studies in Aspergillosis, Allergic Bronchopulmonary with a site in United States is open now. The open studies under Aspergillosis, Allergic Bronchopulmonary, anywhere →

Who these studies take

Of the 10 Aspergillosis, Allergic Bronchopulmonary studies recruiting now, 7 (70%) set no upper age limit and 1 (10%) stops at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Aspergillosis, Allergic Bronchopulmonary with a site in United States as a file.
02

Study summary

A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Itraconazole Administered as a Dry Powder for Inhalation (PUR1900) in Adult Asthmatic Patients With Allergic Bronchopulmonary Aspergillosis

Read the detailed description

This is a randomized, double-blind, multicenter, placebo controlled, multiple-arm study.

Following screening and confirmation of eligibility, subjects will be randomly assigned (1:1:1:1) into 4 arms of 16 subjects each and will receive 10 mg, 20 mg, or 35 mg of PUR1900 or placebo, administered via dry powder inhalation daily for 28 days. The doses of PUR1900 are stated in this protocol as the respective nominal doses of itraconazole.

Subject eligibility for the study will be determined within 28 days before the first dose of study drug (Day 1) and will be confirmed between 9 and 6 days before dosing and again on Day 1.

Eligible subjects will begin daily dosing with study drug (PUR1900 or placebo) on Day 1.

Subjects will return to the study site for visits on Days 2, 7, 14, and 28 and will be dosed at the study site. The remaining daily doses of study drug will be self-administered at home.

A follow-up visit will occur 7 to 10 days after the last dose of study drug.

03

Conditions studied

  • Allergic Bronchopulmonary Aspergillosis

Keywords

  • Aspergillosis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is a male or female, 18 to 75 years old (inclusive) at the time of signing the .
  • Has a of 18.0 to 35.0 kg/m2 (inclusive) at screening.
  • Has a historical diagnosis of asthma, as per the Global Initiative for Asthma (GINA) 2018 update.
  • Has a confirmed historical diagnosis of ABPA, as per the Modified International Society for Human and Animal Mycology (ISHAM) working group 2013 criteria.
  • Is currently considered to be in one of the following stages of ABPA: Stage 2 (Response), Stage 4 (Remission), Stage 5a (Treatment-dependent ABPA), or Stage 5b (-dependent asthma)
  • Has a serum immunoglobulin (Ig) E ≥1000 IU/mL during screening (Visit 1 or Visit 2).
  • Can perform a valid, reproducible spirometry test with demonstration of a prebronchodilator ≥50% of predicted normal for age, sex, race, and height (Quanjer et al 2012) at a screening visit.
  • Has a documented stable asthma medication regimen during screening (Day 28 to Day 1), including SABA, LABA, and LTRA use and inhaled and/or oral GCS.
  • Subjects who are sexually active, male subjects able to father a child, and female subjects of must agree to follow the requirements of this protocol.
  • Can demonstrate the correct inhalation technique for the use of the delivery device at screening and before dosing.

Exclusion criteria

Exclusion Criteria:

  • Is a female of who is pregnant or lactating or who plans to become pregnant during the study. A woman is considered to be of childbearing potential unless she is either permanently sterile (hysterectomy, bilateral salpingectomy, bilateral oophorectomy, bilateral tubal occlusion/ligation) or (had no menses for 12 months without an alternative medical cause).
  • Has a history of life-threatening asthma within the last 5 years, defined as an asthma episode that required intubation and/or was associated with hypercapnia, respiratory arrest, and/or hypoxic seizures.
  • Had an occurrence of asthma or ABPA exacerbations within the 28 days before screening or during the 28-day period before Day 1.
  • Had an occurrence of bacterial, viral, or fungal infection that required systemic (oral or intravenous) antibiotics, antivirals, or antifungals within the 28 days before screening. Topical treatments, other than antifungals, are allowed.
  • Received any medical product in a clinical research study within the previous 3 months before dosing in this study.
  • Has previously received PUR1900.
  • Has a history of any significant drug or alcohol abuse in the past 2 years before screening, as judged by the investigator.
  • Has current tobacco or inhaled marijuana use or history of smoking tobacco or marijuana within the last 6 months before screening.
  • Is a current user of e-cigarettes or has used these products within the last 6 months before screening.
  • Has a positive urine test result for drugs of abuse, alcohol, or cotinine at screening
  • Has a history of allergies to or reactions after dosing of itraconazole or other antifungal azoles.
  • Had a major trauma or surgery within the last 28 days before screening.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    10 mg PUR1900

    Study drug (PUR1900) will be administered orally, using a Dry Powder Inhaler (DPI) specific to the study (RS01 Monodose inhaler)

    Combination Product: PUR1900

  • Experimental
    20 mg PUR1900

    Study drug (PUR1900) will be administered orally, using a Dry Powder Inhaler (DPI) specific to the study (RS01 Monodose inhaler)

    Combination Product: PUR1900

  • Experimental
    35 mg PUR1900

    Study drug (PUR1900) will be administered orally, using a Dry Powder Inhaler (DPI) specific to the study (RS01 Monodose inhaler)

    Combination Product: PUR1900

  • Placebo comparator
    Placebo

    Placebo

    Combination Product: Placebo

Interventions

  • Combination productPUR1900

    PUR1900 contains itraconazole as the active ingredient, and it is formulated as a dry powder for oral inhalation.

  • Combination productPlacebo

    PUR1900 placebo

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events

    Time frame: From Day 1 through Follow Up (which is 7 to 10 days after the last dose)

  2. Incidence of intraday FEV1 declines

    Time frame: From Day 1 through Follow Up (which is 7 to 10 days after the last dose)

  3. Respiratory rate

    Time frame: From Day 1 through Follow Up (which is 7 to 10 days after the last dose)

  4. Blood pressure

    Systolic pressure over diastolic pressure

    Time frame: From Day 1 through Follow Up (which is 7 to 10 days after the last dose)

  5. Heart rate

    Beats per minute

    Time frame: From Day 1 through Follow Up (which is 7 to 10 days after the last dose)

  6. Oxygen saturation

    As a percentage

    Time frame: From Day 1 through Follow Up (which is 7 to 10 days after the last dose)

  7. Physical examination findings

    Physician's notes

    Time frame: From Day 1 through Follow Up (which is 7 to 10 days after the last dose)

  8. Clinical laboratory test results

    Lab reports with any out of range results flagged

    Time frame: From Day 1 through Follow Up (which is 7 to 10 days after the last dose)

  9. 12-Lead electrocardiogram findings

    ECG report and tracing

    Time frame: From Day 1 through Follow Up (which is 7 to 10 days after the last dose)

Secondary outcomes

  1. Sputum concentrations of itraconazole and hydroxy-itraconazole

    Time frame: Day 2 to Day 28

  2. Sputum eosinophils

    Time frame: (Day -9 to Day -6) to Day 28

  3. To evaluate the effect of PUR1900 on pulmonary function following single- and multiple-dose administration of PUR1900

    Time frame: Day 1 to Day 28

  4. Asthma Control Questionnaire-6 (ACQ 6)

    Scores range between 0 (totally controlled) and 6 (severely uncontrolled).

    Time frame: Day 1 to Day 28

  5. Change from baseline (Day 1) to Day 28 in A fumigatus burden in sputum

    As assessed by quantitative PCR and sputum culture

    Time frame: Day 1 to Day 28

  6. Cmax (maximum observed concentration in plasma)

    Time frame: Day 1 to Day 28

  7. Tmax (time to maximum concentration in plasma)

    Time frame: Day 1 to Day 28

  8. AUC (area under the concentration-time curve)

    Time frame: Day 1 to Day 28

  9. CL/F (clearance)

    Time frame: Day 1 to Day 28

  10. Vz/F (apparent volume of distribution)

    Time frame: Day 1 to Day 28

07

Study locations

20 sites
  • National Jewish Health
    Denver, Colorado 80206, United States
  • Yale University School of Medicine
    New Haven, Connecticut 06520, United States
  • Integrity Clinical Research Center Inc.
    Hialeah, Florida 33015, United States
  • Heuer M.D Research Inc.
    Miami Lakes, Florida 32819, United States
  • Infinite Clinical Trials
    Roswell, Georgia 30076, United States
  • University Consultants In Allergy and Immunology
    Chicago, Illinois 60612, United States
  • Laporte County Institute for Clinical Research
    Michigan City, Indiana 46360, United States
  • Montefiore Medical Center
    Bronx, New York 10461, United States
  • University of Texas Medical Branch at Galveston
    Galveston, Texas 77555, United States
  • John Hunter Hospital
    New Lambton, New South Wales 2305, Australia
  • Mater Private Hospital Brisbane
    Brisbane, Queensland 4101, Australia
  • Yashoda Hospital
    Hyderabad, Andhra Pradesh 500082, India
  • Shree Hospital And Critical Care Centre
    Nagpur, Maharashtra 440009, India
  • SMS Medical College and Hospital
    Jaipur, Rajasthan 302016, India
  • Centrum Medycyny Oddechowej Mroz sp. j.
    Bialystok, Podlaskie 15-044, Poland
  • Uniwersyteckie Centrum Kliniczne - PPDS
    Gdansk, Pomorskie 80-952, Poland
  • PULMAG Arkadiusz Brodowski, Grzegorz Gasior S. C.
    Sosnowiec, Slaskie 41-200, Poland
  • Centrum Alergologii Teresa Hofman
    Poznań, Wielkopolskie 60-214, Poland
  • Birmingham Heartlands Hospital
    Birmingham, West Midlands B9 5SS, United Kingdom
  • Wythenshawe Hospital - PPDS
    Manchester, M23 9LT, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2019 to primary completion in Jul 2020, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2019
First posted
May 23, 2019
StartActual
Jul 31, 2019
Primary completionActual
Jul 14, 2020
CompletionActual
Jul 14, 2020
Results delay requested
Jul 8, 2021
Last update
Aug 27, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03960606
Lead sponsor
Pulmatrix Inc.
Responsible party
Sponsor
First posted
May 23, 2019
Start date
Jul 31, 2019
Primary completion
Jul 14, 2020
Completion
Jul 14, 2020
Last update
Aug 27, 2021

Study contacts

William J. Calhoun, MD
principal investigator · University of Texas Medical Branch Galveston, TX 77555
David Denning, FRCP, FRC Path, FIDSA, FMedSci
principal investigator · Director, National Aspergillosis Centre Manchester, Wythenshawe M23 9LT, UK

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion